Published Online: Saturday, April 1, 2006

The pharmaceutical industry's commitment to finding new medicines climbed to a new high last year, as drug manufacturer-sponsored research and development (R&D) spending hit a record $51.3 billion in 2005.

Most of that R&D investment reflects spending on new medicines by member companies of the Pharmaceutical Research and Manufacturers of America (PhRMA)—a group that has increased its investment in new drug research each year for the past quarter century.

PhRMA's members paid out a record $39.4 billion in 2005 (up from $37 billion in 2004 and from $2 billion in 1980). According to the association, last year's R&D spending amounted to more than 19% of the total sales of PhRMA members.

"America's research-based biopharmaceutical companies once again lead the world in investing in the hunt for new cures and treatments," said PhRMA's president and chief executive officer, Billy Tauzin. "The R&D investment made by PhRMA member companies is one reason that Americans today live longer, healthier, and more productive lives."

Latest Articles
The Advisory Committee on Immunization Practices recently updated the recommended interval between the 13-valeant pneumococcal conjugate vaccine and the 23-valeant pneumococcal polysaccharide vaccine in low-risk elderly patients.
Driving under the influence of prescription drugs may be just as dangerous as driving under the influence of alcohol.
Retrospective drug utilization review programs can reduce potentially unsafe concomitant opioid and central nervous system (CNS) medication use.
Chlamydia, gonorrhea, and syphilis are on the rise for the first time since 2006, according to the US Centers for Disease Control and Prevention.
Latest Issues